首页> 外文期刊>Journal of Pathology: Journal of the Pathological Society of Great Britain and Ireland >Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium.
【24h】

Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium.

机译:9q32-33(DBC1位点)杂合性丧失在原发性低浸润性低恶性膀胱乳头状尿路上皮肿瘤和低度膀胱尿路上皮癌及其相关的正常尿路上皮中。

获取原文
获取原文并翻译 | 示例
           

摘要

Tumour recurrence has a major impact on patients with non-invasive papillary urothelial tumours of the bladder. To explore the role of DBC1 (deleted in bladder cancer 1 locus), a candidate tumour suppressor gene located at 9q32-33, as prognostic marker we have performed loss of heterozygosity (LOH) testing in 49 patients with primary papillary urothelial tumours and associated normal urothelium. Data from the 38 tumours and 11 specimens of normal urothelium that were informative in the LOH study (D9S195 marker) showed that LOH in urothelium (45.4%) but not in non-invasive tumours (60.5%) was associated with tumour recurrence (p = 0.026) but not to grade or progression. Also, tumours whose normal urothelium had LOH were larger (p = 0.020) and showed cyclin D1 over-expression (p = 0.032). Non-significant increased expression of p53, p21Waf1, apoptotic index and tumour proliferation, and decreased expression of p27Kip1 or cyclin D3 also characterized tumours whose normal urothelium had LOH. The expressionof these G(1)-S modulators, apoptotic index and tumour proliferation was more heterogeneous in papillary urothelial tumours, irrespective of having retained heterozygosity or LOH. Also, Bax expression decreased in papillary urothelial tumours having LOH (p = 0.0473), but Bcl-2 was unrelated to LOH status. In addition, FGFR3 protein expression decreased in LOH tumours (p = 0.036) and in those having LOH in their normal urothelium (p = 0.022). FGFR3 immunohistochemical expression was validated by western blot in selected cases. The survival analysis selected LOH in normal urothelium as a marker of disease-free survival (log-rank 5.32, p = 0.021), progression-free survival (log-rank 3.97, p = 0.046) and overall survival (log-rank 4.26, p = 0.038); LOH in tumours was significant in progression-free survival (log-rank 3.83, p = 0.042). It is concluded that LOH at the DBC1 locus in normal urothelium seems to be relevant in the prognosis of non-invasive papillary tumours of the bladder via selecting cases with increased proliferation, frequent alterations of the G(1)-S phase modulators, and decreased FGFR3 protein expression. Copyright (c) 2008 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
机译:肿瘤复发对患有膀胱非侵入性乳头尿路上皮肿瘤的患者有重大影响。为了探讨位于9q32-33的候选肿瘤抑制基因DBC1(在膀胱癌1位点中删除)的作用,作为预后标志物,我们对49例原发性乳头状尿路上皮肿瘤和相关正常患者进行了杂合性缺失(LOH)检测尿路上皮。 LOH研究(D9S195标记)的38份肿瘤和11份正常尿路上皮标本的数据表明,尿路上皮(45.4%)但非浸润性肿瘤(60.5%)中的LOH与肿瘤复发相关(p = 0.026),而不是评分或进度。同样,正常尿路上皮具有LOH的肿瘤更大(p = 0.020),并显示cyclin D1过表达(p = 0.032)。 p53,p21Waf1,细胞凋亡指数和肿瘤增殖的非显着增加,以及p27Kip1或cyclin D3的表达下降也表明正常尿路上皮具有LOH。这些G(1)-S调节剂的表达,凋亡指数和肿瘤增殖在乳头状尿路上皮肿瘤中更加异质,无论是否保留杂合性或LOH。同样,在具有LOH的乳头尿路上皮肿瘤中,Bax表达下降(p = 0.0473),但Bcl-2与LOH状态无关。此外,FGFR3蛋白表达在LOH肿瘤(p = 0.036)和正常尿路上皮中有LOH的肿瘤中表达降低(p = 0.022)。 FGFR3免疫组织化学表达在选定的病例中通过蛋白质印迹验证。生存分析选择正常尿路上皮中的LOH作为无病生存的指标(对数排名5.32,p = 0.021),无进展生存率(对数排名3.97,p = 0.046)和总生存率(对数排名4.26, p = 0.038);肿瘤中的LOH在无进展生存期中显着(对数秩3.83,p = 0.042)。结论:正常尿路上皮中DBC1位点的LOH通过选择增生,G(1)-S期调节剂频繁改变和减少的病例,似乎与膀胱非侵入性乳头状肿瘤的预后有关FGFR3蛋白表达。版权所有(c)2008英国和爱尔兰病理学会。由John Wiley&Sons,Ltd.出版

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号